Laura Chambers, Dennis Grencewicz, Daniel Spakowicz
{"title":"从 \"便便 \"到 \"希望\"：粪便微生物群移植支持实体瘤免疫疗法的再敏感化。","authors":"Laura Chambers, Dennis Grencewicz, Daniel Spakowicz","doi":"10.1016/j.chom.2024.07.015","DOIUrl":null,"url":null,"abstract":"<p><p>Fecal microbiota transplants (FMTs) recently entered the cancer therapeutics field as a method to resensitize treatment-resistant melanoma patients to immune checkpoint inhibitors (ICIs). In this issue of Cell Host & Microbe, Kim and colleagues extend its utility to other solid tumors, including esophageal and hepatocellular carcinomas.<sup>1</sup>.</p>","PeriodicalId":93926,"journal":{"name":"Cell host & microbe","volume":"32 8","pages":"1217-1218"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"From poo to promise: Fecal microbiota transplants support immunotherapy re-sensitization in solid tumors.\",\"authors\":\"Laura Chambers, Dennis Grencewicz, Daniel Spakowicz\",\"doi\":\"10.1016/j.chom.2024.07.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fecal microbiota transplants (FMTs) recently entered the cancer therapeutics field as a method to resensitize treatment-resistant melanoma patients to immune checkpoint inhibitors (ICIs). In this issue of Cell Host & Microbe, Kim and colleagues extend its utility to other solid tumors, including esophageal and hepatocellular carcinomas.<sup>1</sup>.</p>\",\"PeriodicalId\":93926,\"journal\":{\"name\":\"Cell host & microbe\",\"volume\":\"32 8\",\"pages\":\"1217-1218\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell host & microbe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chom.2024.07.015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell host & microbe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.chom.2024.07.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
From poo to promise: Fecal microbiota transplants support immunotherapy re-sensitization in solid tumors.
Fecal microbiota transplants (FMTs) recently entered the cancer therapeutics field as a method to resensitize treatment-resistant melanoma patients to immune checkpoint inhibitors (ICIs). In this issue of Cell Host & Microbe, Kim and colleagues extend its utility to other solid tumors, including esophageal and hepatocellular carcinomas.1.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
